The perceptions of risks and benefits of Infliximab and Leukocytapheresis by Japanese patients with Inflammatory Bowel Disease

被引：0
|
作者：
Fukunaga, K.
Matsumoto, T.
Matsui, T. [1 ]
Fujiyama, Y. [2 ]
Takayama, T. [3 ]
Ashida, T. [4 ]
Kohgo, Y. [5 ]
Hibi, T. [6 ]
Watanabe, M. [7 ]
机构：
[1] Fukuoka Univ, Fac Med, Dept Gastroenterol, Fukuoka 81401, Japan
[2] Shiga Univ Med Sci, Dept Gastroenterol, Shiga, Japan
[3] Univ Tokushima, Fac Med, Dept Gastroenterol, Tokushima 770, Japan
[4] Sapporo Higashi Tokusyukai Hosp, IBD Ctr, Sapporo, Hokkaido, Japan
[5] Asahikawa Med Coll, Dept Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido 078, Japan
[6] Keio Univ, Sch Med, Dept Gastroenterol, Tokyo, Japan
[7] Tokyo Med & Dent Univ, Dept Gastroenterol, Tokyo, Japan
来源：
INFLAMMATORY BOWEL DISEASES | 2009年 / 15卷 / 12期
关键词：
D O I：
10.1097/00054725-200912002-00056
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [1] Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
    Siegel, CoreyA.
    Levy, L. Campbell
    Mackenzie, Todd A.
    Sands, Bruce E.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : 1 - 6
  • [2] Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
    Siegel, Corey A.
    Levy, Campbell
    Mackenzie, Todd A.
    Sands, Bruce E.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S438 - S438
  • [3] Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease
    Sandborn, WJ
    Loftus, EV
    [J]. GUT, 2004, 53 (06) : 780 - 782
  • [4] Benefits and risks of immunosuppression in inflammatory bowel disease
    Rogler, G.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2008, 133 (38) : 1917 - 1921
  • [5] Therapeutic leukocytapheresis for inflammatory bowel disease
    Saniabadi, Abbi R.
    Hanai, Hiroyuki
    Fukunaga, Ken
    Sawada, Koji
    Shima, Chikako
    Bjarnason, Ingvar
    Lofberg, Robert
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2007, 37 (02) : 191 - 200
  • [6] Treatment of inflammatory bowel disease by leukocytapheresis
    Gerceker, Emre
    Yuceyar, Hakan
    Kasap, Elmas
    Demirci, Ufuk
    Ekti, Burcu Ceren
    Aydogdu, Ismet
    Miskioglu, Mine
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2017, 56 (03) : 421 - 426
  • [7] Communicating the benefits and risks of inflammatory bowel disease therapy to patients and families
    Picoraro, Joseph A.
    Rosh, Joel R.
    [J]. CURRENT OPINION IN PEDIATRICS, 2017, 29 (05) : 572 - 577
  • [8] Leukocytapheresis in patients with inflammatory bowel diseases
    Wozniak, Malgorzata
    Kurnatowska, Ilona
    Malecka-Panas, Ewa
    Talar-Wojnarowska, Renata
    [J]. GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2021, 16 (02): : 99 - 105
  • [9] Leukocytapheresis as promising therapy for inflammatory bowel disease
    Caprilli, R.
    D'Ovidio, V.
    [J]. DIGESTIVE AND LIVER DISEASE, 2007, 39 (05) : 435 - 437
  • [10] Infliximab pharmacokinetics in inflammatory Bowel disease patients
    Ternant, David
    Aubourg, Alexandre
    Magdelaine-Beuzelin, Charlotte
    Degenne, Danielle
    Watier, Herve
    Picon, Laurence
    Paintaud, Gilles
    [J]. THERAPEUTIC DRUG MONITORING, 2008, 30 (04) : 523 - 529
12345